Title of article :
Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population: A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry
Author/Authors :
Urban، نويسنده , , Philip and Abizaid، نويسنده , , Alexandre and Banning، نويسنده , , Adrian and Bartorelli، نويسنده , , Antonio L. and Baux، نويسنده , , Ana Cebrian and D?av?k، نويسنده , , Vladim?r and Ellis، نويسنده , , Stephen and Gao، نويسنده , , Runlin and Holmes، نويسنده , , David and Jeong، نويسنده , , Myung Ho and Legrand، نويسنده , , Victor and Neumann، نويسنده , , Franz-Josef and Nyaker، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2011
Abstract :
Objectives
m of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES).
ound
thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated worldwide are unclear.
s
S were implanted in 15,147 patients who were entered in a multinational registry. We analyzed the incidence of: 1) definite and probable ST as defined by the Academic Research Consortium; and 2) MB, with the STEEPLE (Safety and efficacy of Enoxaparin in PCI) definition, together with their relation to dual antiplatelet therapy (DAPT) and to 1-year clinical outcomes.
s
an age of the sample was 62 ± 11 years, 30.4% were diabetic, 10% had a Charlson comorbidity index ≥3, and 44% presented with acute coronary syndrome or myocardial infarction. At 1 year, the reported compliance with DAPT as recommended by the European Society of Cardiology guidelines was 86.3%. Adverse event rates were: ST 1.0%, MB 1.0%, mortality 1.7%, myocardial infarction 1.9%, and target lesion revascularization 2.3%. Multivariate analysis identified 9 correlates of ST and 4 correlates of MB. Advanced age and a high Charlson index were associated with an increased risk of both ST and MB. After ST, the 7-day and 1-year all-cause mortality was 30% and 35%, respectively, versus 1.5% and 10% after MB. Only 2 of 13,749 patients (0.015%) experienced both MB and ST during the entire 1-year follow-up period.
sions
s worldwide population treated with ≥1 SES, the reported compliance with DAPT was good, and the incidence of ST and MB was low. Stent thrombosis and MB very rarely occurred in the same patient. (The e-SELECT Registry: a Multicenter Post-Market Surveillance; NCT00438919)
Keywords :
Coronary stent , Sirolimus-eluting stent , Stent thrombosis , drug-eluting stent , bleeding complication , Antithrombotic therapy
Journal title :
JACC (Journal of the American College of Cardiology)
Journal title :
JACC (Journal of the American College of Cardiology)